- Home
- ALLO vs LFCR Comparison
ALLO vs LFCR Comparison
Compare ALLO & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- LFCR
- Stock Information
- Founded
- ALLO 2017
- LFCR 1986
- Country
- ALLO United States
- LFCR United States
- Employees
- ALLO N/A
- LFCR N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- LFCR Health Care
- Exchange
- ALLO Nasdaq
- LFCR Nasdaq
- Market Cap
- ALLO 252.9M
- LFCR 255.1M
- IPO Year
- ALLO 2018
- LFCR N/A
- Fundamental
- Price
- ALLO $1.21
- LFCR $6.67
- Analyst Decision
- ALLO Buy
- LFCR Buy
- Analyst Count
- ALLO 12
- LFCR 4
- Target Price
- ALLO $8.80
- LFCR $8.00
- AVG Volume (30 Days)
- ALLO 2.9M
- LFCR 198.3K
- Earning Date
- ALLO 11-13-2025
- LFCR 10-03-2025
- Dividend Yield
- ALLO N/A
- LFCR N/A
- EPS Growth
- ALLO N/A
- LFCR N/A
- EPS
- ALLO N/A
- LFCR N/A
- Revenue
- ALLO N/A
- LFCR $128,867,000.00
- Revenue This Year
- ALLO N/A
- LFCR $4.72
- Revenue Next Year
- ALLO $100.00
- LFCR $10.97
- P/E Ratio
- ALLO N/A
- LFCR N/A
- Revenue Growth
- ALLO N/A
- LFCR 0.47
- 52 Week Low
- ALLO $0.86
- LFCR $4.76
- 52 Week High
- ALLO $3.78
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- ALLO 49.04
- LFCR 45.24
- Support Level
- ALLO $1.21
- LFCR $6.69
- Resistance Level
- ALLO $1.26
- LFCR $6.94
- Average True Range (ATR)
- ALLO 0.08
- LFCR 0.23
- MACD
- ALLO -0.01
- LFCR 0.04
- Stochastic Oscillator
- ALLO 14.18
- LFCR 68.85
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.